Pembrolizumab in Treating Patients With Stage III-IV High-Risk Melanoma Before and After Surgery



Status:Recruiting
Conditions:Skin Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:4/4/2019
Start Date:December 6, 2018
End Date:September 1, 2022

Use our guide to learn which trials are right for you!

A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant MK-3475 (Pembrolizumab) for Clinically Detectable Stage III-IV High-Risk Melanoma

This phase II trial studies how pembrolizumab works before and after surgery in treating
patients with stage III-IV high-risk melanoma. Immunotherapy with monoclonal antibodies, such
as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with
the ability of tumor cells to grow and spread. Giving pembrolizumab before and after surgery
may work better in treating melanoma.

PRIMARY OBJECTIVES:

I. To compare event-free survival (EFS) in patients with high-risk resectable melanoma
randomized to neoadjuvant MK-3475 (pembrolizumab) with patients randomized to adjuvant
MK-3475 (pembrolizumab).

SECONDARY OBJECTIVES:

I. To assess the frequency and severity of toxicities on each of the arms. II. To compare
between arms overall survival (OS), disease control at 24 weeks, locoregional control in the
surgical site(s), and total number of MK-3475 (pembrolizumab) doses received.

III. On the neoadjuvant arm, to estimate the pathologic response rate, the Response
Evaluation Criteria in Solid Tumors (RECIST) 1.1 response rate (confirmed complete response
[CR] and partial response [PR]), and the immune-related (i)RECIST response rate (confirmed CR
and PR), before surgical resection; to compare definitions of pathologic partial response;
and to evaluate the association between pathologic response and EFS and OS.

IV. To describe the proportion of patients on each arm who received the surgery planned at
randomization.

ADDITIONAL OBJECTIVES:

I. To bank tumor tissue and whole blood in anticipation of future correlative studies in this
patient population.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Within 84 days after surgical resection, patients receive pembrolizumab intravenously
(IV) over 30 minutes on day 1. Treatment repeats every 3 weeks for 18 courses in the absence
of disease progression or unacceptable toxicity.

ARM II: Patients receive pembrolizumab IV over 30 minutes on day 1 every 3 weeks for 3
courses, then undergo surgical resection within 3 weeks. Within 84 days, patients receive
pembrolizumab IV over 30 minutes every 3 weeks for 15 courses in the absence of disease
progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 3 and 12 weeks, then every
3, 6, or 12 months for up to 10 years.

Inclusion Criteria:

- STEP 1 REGISTRATION (RANDOMIZATION)

- Patients must have resectable melanoma in order to be eligible for this study.
Patients must have clinically detectable stage III (clinically detectable N1b, N1c,
N2b, N2c, N3b and N3c) or stage IV resectable melanoma. Patients with melanoma of
mucosal or acral origin are eligible. Patients with melanoma of uveal origin are not
eligible. Patients with a history of brain metastases are not eligible. Clinically
detectable is defined as disease that is apparent and measurable via physical
examination or radiographic imaging.

- Patients are eligible for this trial either at initial presentation of their melanoma
or at the time of the first detected nodal, satellite/in-transit, distant metastases,
or recurrent disease in prior lymphadenectomy basin or distant site. Nodal,
satellite/in-transit metastasis, distant metastases or disease in a prior complete
lymphadenectomy basin must have been confirmed histologically by hematoxylin (H) &
eosin (E) stained slides.

- Patients with multiple regional nodal basin involvement are eligible. Gross or
microscopic extracapsular nodal extension is permitted.

- Patients must not have received previous neoadjuvant treatment for their melanoma.
Patients may have received prior non-immunotherapy adjuvant therapy. Patients must not
have had prior immunotherapy including, but not limited to ipilimumab, interferon
alfa-2b, high dose, pegylated interferon (PEG-IFN), anti-PD-1, anti-PD-L1
intra-tumoral, or vaccine therapies. Patients must not be planning to receive any of
the prohibited therapies during treatment phases on the study.

- Patients must not be planning to receive concomitant other biologic therapy, hormonal
therapy, other chemotherapy, surgery, while on protocol therapy.

- Patients may have received prior radiation therapy, including after prior surgical
resection. All adverse events associated with prior surgery and radiation therapy must
have resolved to =< grade 1 prior to randomization.

- All patients must have disease status documented by a complete physical examination
and imaging studies within 42 days prior to randomization. Imaging studies must
include a total body positron emission tomography (PET)-computerized tomography (CT)
scan that is of diagnostic quality with iodine contrast-enhanced images (with or
without brain) or a CT of the chest, abdomen and pelvis with intravenous contrast. For
patients with melanoma arising from the head and neck, dedicated neck imaging (CT with
intravenous contrast or iodine contrast-enhanced PET-CT through the region) is
required. If the patient has unknown primary with disease in the axilla, neck imaging
is required to assure region is clear of cancer. CT imaging should be done with
intravenous contrast if there are no contraindications for it. Any other
clinically-indicated imaging studies if performed (e.g. bone scan) must show no
evidence of disease.

- All patients must have a CT or magnetic resonance imaging (MRI) of the brain within 42
days prior to randomization. The brain CT or MRI should be performed with intravenous
contrast (unless contraindicated).

- Absolute neutrophil count (ANC) >= 1,500/microliter (mcL) (within 42 days prior to
randomization).

- Platelets >= 100,000/mcL (within 42 days prior to randomization).

- Hemoglobin >= 10 g/dL (within 42 days prior to randomization).

- Total bilirubin =< 1.5 x institutional upper limit of normal (IULN) (except patients
with Gilbert's syndrome, who must have a total bilirubin < 3.0 mg/dL) (within 42 days
prior to randomization).

- Serum glutamic-oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) and
serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 2 x
IULN (within 42 days prior to randomization).

- Alkaline phosphatase =< 2 x IULN (within 42 days prior to randomization).

- Patients must have lactate dehydrogenase (LDH) performed within 42 days prior to
randomization.

- Patients must have adequate creatinine clearance as evidenced by creatinine clearance
(CrCl) > 30 mL/min within 42 days prior to randomization.

- Patients must have Zubrod performance status =< 2.

- Patients must not have a history of (non-infectious) pneumonitis that required
steroids or current pneumonitis.

- Patients must not have an active infection requiring systemic therapy.

- Patients must not have active autoimmune disease that has required systemic treatment
in past 2 years (i.e., with use of disease modifying agents, corticosteroids or
immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or
physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency,
etc.) is not considered a form of systemic treatment.

- Patients must not have received live vaccines within 42 days prior to randomization.
Examples of live vaccines include, but are not limited to, the following: measles,
mumps, rubella, chicken pox, shingles, yellow fever, rabies, Bacillus Calmette-Guerin
(BCG), and typhoid (oral) vaccine. Seasonal influenza vaccines for injection are
generally killed virus vaccines and are allowed; however, intranasal influenza
vaccines (e.g., Flu-Mist) are live attenuated vaccines, and are not allowed.

- Patients known to be human immunodeficiency virus (HIV) positive are eligible if they
meet the following criteria within 30 days prior to randomization: stable and adequate
CD4 counts (>= 350 mm^3), and serum HIV viral load of < 25,000 IU/ml. Patients may be
on or off anti-viral therapy so long as they meet the CD4 count criteria.

- Patients must not have known active hepatitis B virus (HBV) or hepatitis C virus (HCV)
infection prior to randomization. Note: No testing for hepatitis B and hepatitis C is
required unless mandated by local health authority.

- Prior malignancy is allowed providing it does not require concurrent therapy.

- Women of childbearing potential must have a negative urine or serum pregnancy test
within 28 days prior to randomization. Women/men of reproductive potential must have
agreed to use an effective contraceptive method for the course of the study through
120 days after the last dose of study medication. Should a woman become pregnant or
suspect she is pregnant while she or her partner is participating in this study, she
should inform her treating physician immediately. A woman is considered to be of
"reproductive potential" if she has had menses at any time in the preceding 12
consecutive months. In addition to routine contraceptive methods, "effective
contraception" also includes heterosexual celibacy and surgery intended to prevent
pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy,
bilateral oophorectomy, or bilateral tubal ligation. However, if at any point a
previously celibate patient chooses to become heterosexually active during the time
period for use of contraceptive measures outlined in the protocol, he/she is
responsible for beginning contraceptive measures. Patients must not be pregnant or
nursing due to unknown teratogenic side effects.

- Patients must be deemed medically fit to undergo surgery by the treating
medical/surgical team.

- Patients must be willing to submit the following surgical specimens: either all tissue
blocks from the surgical specimen or two slides per block ([1] hematoxylin and eosin
[H&E] slide and [1] unstained slide OR [2] unstained slides if H&E stained slides
cannot be provided).

- Patients must be offered the opportunity to participate in specimen banking.

- Patients must be informed of the investigational nature of this study and must sign
and give written informed consent for this protocol in accordance with institutional
and federal guidelines.

- As a part of the Oncology Patient Enrollment Network (OPEN) randomization process the
treating institution's identity is provided in order to ensure that the current
(within 365 days) date of institutional review board approval for this study has been
entered in the system.

- STEP 2 REGISTRATION (SURGERY)

- Patients randomized to arm 2 (neoadjuvant arm) must be willing to submit tissue to
determine pathologic response regardless of number of pre-operative doses of MK-3475
(pembrolizumab) received. Determination of pathologic response cannot be done on less
than the full surgical specimen.

- Patients must have disease assessments by PET-CT with iodinated CT contrast (i.e.
diagnostic quality CT) or CT chest/abdomen/pelvis with IV contrast, and neck CT with
IV contrast if primary head and neck melanoma, performed within 42 days (+/- 1 week)
before surgery. MRI combined with non-contrast CT is an acceptable alternative for
patients with CT contrast allergy, but imaging must encompass total body.

- STEP 3 REGISTRATION (ADJUVANT THERAPY)

- Patients must have undergone surgery prior to Step 3 registration. The Step 2 surgery
must have completely resected their melanoma.

- Patients with gross positive residual disease at the time of surgery do not
qualify as having disease-free status, and, therefore, such patients are not
eligible to register for adjuvant therapy.

- Patients with microscopic residual disease (i.e., positive margins) can be
treated with re-excision or radiation, per site discretion, to render the patient
disease-free prior to registration of adjuvant therapy.

- Disease-free status must be documented by a complete physical examination and
radiographic imaging studies within 60 days prior to Step 3 registration. Imaging
studies must include a total body PET-CT that is of diagnostic quality (i.e.,
iodinated contrast), or a CT of the chest, abdomen, and pelvis.

- For patients with melanoma arising from the head and neck, dedicated neck imaging
(CT with IV contrast with PET-CT through the region) is required.

- If the patient has had unknown primary with disease in the axilla, neck imaging
is required to assure the region is clear of cancer.

- CT imaging should be done with intravenous contrast if there are no
contraindications for it.

- Any other clinically-indicated imaging studies if performed (e.g., bone scan)
must show no evidence of disease.

- Patients must be registered to step 3 no more than 84 days after date of surgery.
We found this trial at
506
sites
4950 Essen Lane
Baton Rouge, Louisiana 70809
Principal Investigator: David S. Hanson
Phone: 225-757-0343
?
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
2545 Schoenersville Rd
Bethlehem, Pennsylvania 18017
(484) 884-2200
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Lehigh Valley Hospital - Muhlenberg At Lehigh Valley Health Network, we continually go the extra...
?
mi
from
Bethlehem, PA
Click here to add this to my saved trials
Bremerton, Washington 98310
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Bremerton, WA
Click here to add this to my saved trials
666 Elm Street
Buffalo, New York 14263
(716) 845-2300
Principal Investigator: Marc S. Ernstoff
Phone: 800-767-9355
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
1 Hurley Plaza
Flint, Michigan 48503
(810) 262-9000
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Hurley Medical Center From its founding in 1908, Hurley Medical Center has devoted itself to...
?
mi
from
Flint, MI
Click here to add this to my saved trials
4725 North Federal Highway
Fort Lauderdale, Florida 33308
(954) 771-8000
Principal Investigator: Jose Lutzky
Phone: 954-267-7750
Holy Cross Hospital While spirituality plays an essential role in the way that we minister...
?
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
100 Michigan Street Northeast
Grand Rapids, Michigan 49503
616.391.9000
Principal Investigator: Kathleen J. Yost
Helen DeVos Children's Hospital at Spectrum Health Helen DeVos Children's Hospital, located in Grand Rapids,...
?
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
2500 N State St
Jackson, Mississippi 39216
(601) 984-1000
Principal Investigator: Kelly J. Wilkinson
Phone: 601-815-6700
University of Mississippi Medical Center The University of Mississippi Medical Center, located in Jackson, is...
?
mi
from
Jackson, MS
Click here to add this to my saved trials
524 South Park Street
Kalamazoo, Michigan 49007
(269) 341-7654
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
Bronson Methodist Hospital Our healthcare system serves patients and families throughout southwest Michigan and northern...
?
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
200 North Park Street
Kalamazoo, Michigan 49007
(269) 382-2500
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
West Michigan Cancer Center In 1994, Borgess Health Alliance and Bronson Healthcare Group opened the...
?
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
1800 West Charleston Boulevard
Las Vegas, Nevada 89102
(702) 383-2000
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
University Medical Center of Southern Nevada University Medical Center is dedicated to providing the highest...
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
4805 Northeast Glisan Street
Portland, Oregon 97213
(503) 215-1111
Principal Investigator: Gary E. Goodman
Phone: 503-215-2614
Providence Portland Medical Center We strive to give those we serve exceptional, compassionate health care...
?
mi
from
Portland, OR
Click here to add this to my saved trials
Seattle, Washington 98104
Principal Investigator: Gary E. Goodman
Phone: 206-215-3086
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Aberdeen, Washington 98520
Principal Investigator: Gary E. Goodman
Phone: 360-412-8958
?
mi
from
Aberdeen, WA
Click here to add this to my saved trials
Abilene, Texas 79601
Principal Investigator: Ke Ning
Phone: 325-670-6340
?
mi
from
Abilene, TX
Click here to add this to my saved trials
Allentown, Pennsylvania 18103
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
?
mi
from
Allentown, PA
Click here to add this to my saved trials
Amarillo, Texas 79106
Principal Investigator: Anita Ravipati
Phone: 806-212-1985
?
mi
from
Amarillo, TX
Click here to add this to my saved trials
Anaconda, Montana 59711
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
?
mi
from
Anaconda, MT
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99504
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 98508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
1500 East Medical Center Drive
Ann Arbor, Michigan 48109
800-865-1125
Principal Investigator: Christopher D. Lao
University of Michigan Comprehensive Cancer Center The U-M Comprehensive Cancer Center's mission is the conquest...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
5301 McAuley Drive
Ann Arbor, Michigan 48197
734-712-3456
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
Saint Joseph Mercy Hospital St. Joseph Mercy Ann Arbor Hospital is a 537-bed teaching hospital...
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
921 North Oak Park Boulevard
Arroyo Grande, California 93420
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
?
mi
from
Arroyo Grande, CA
Click here to add this to my saved trials
Aurora, Colorado 80012
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
?
mi
from
Aurora, CO
Click here to add this to my saved trials
1501 S Potomac St
Aurora, Colorado 80012
(303) 695-2600
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Medical Center of Aurora At The Medical Center of Aurora and Centennial Medical Plaza patients...
?
mi
from
Aurora, CO
Click here to add this to my saved trials
2000 Ogden Ave
Aurora, Illinois 60504
(630) 978-6200
Principal Investigator: Kendrith M. Rowland
Phone: 630-978-6212
Rush - Copley Medical Center Rush-Copley is proud to be the leading provider of health...
?
mi
from
Aurora, IL
Click here to add this to my saved trials
Aventura, Florida 33180
Principal Investigator: Jose Lutzky
Phone: 305-674-2625
?
mi
from
Aventura, FL
Click here to add this to my saved trials
3325 Pocahontas Road
Baker City, Oregon 97814
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
?
mi
from
Baker City, OR
Click here to add this to my saved trials
Ballwin, Missouri 63011
Principal Investigator: Jay W. Carlson
Phone: 314-251-7058
?
mi
from
Ballwin, MO
Click here to add this to my saved trials
489 State St
Bangor, Maine 04401
(207) 973-7000
Principal Investigator: Thomas H. Openshaw
Phone: 207-973-4274
Eastern Maine Medical Center Located in Bangor, Eastern Maine Medical Center (EMMC) serves communities throughout...
?
mi
from
Bangor, ME
Click here to add this to my saved trials
4305 New Shepherdsville Road
Bardstown, Kentucky 40004
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Bardstown, KY
Click here to add this to my saved trials
Baton Rouge, Louisiana 70809
Principal Investigator: David S. Hanson
Phone: 225-215-1353
?
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Baton Rouge, Louisiana 70809
Principal Investigator: David S. Hanson
Phone: 225-215-1353
?
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Baton Rouge, Louisiana 70805
Principal Investigator: David S. Hanson
Phone: 225-215-1353
?
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
265 Fremont St
Battle Creek, Michigan 49017
(269) 245-8166
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
Bronson Battle Creek As a proud member of the Battle Creek community, we believe everyone...
?
mi
from
Battle Creek, MI
Click here to add this to my saved trials
3535 Pentagon Boulevard
Beavercreek, Ohio 45431
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
?
mi
from
Beavercreek, OH
Click here to add this to my saved trials
Bellingham, Washington 98225
Principal Investigator: Gary E. Goodman
Phone: 360-715-4133
?
mi
from
Bellingham, WA
Click here to add this to my saved trials
800 Farson Street
Belpre, Ohio 45714
(740) 401-0417
Principal Investigator: Timothy D. Moore
Phone: 800-523-3977
Strecker Cancer Center-Belpre The Memorial Health System's Strecker Cancer Center, Belpre combines the clinical expertise...
?
mi
from
Belpre, OH
Click here to add this to my saved trials
Bemidji, Minnesota 56601
Principal Investigator: Preston D. Steen
Phone: 218-333-5000
?
mi
from
Bemidji, MN
Click here to add this to my saved trials
Bend, Oregon 97701
Principal Investigator: Gary E. Goodman
Phone: 541-706-2909
?
mi
from
Bend, OR
Click here to add this to my saved trials
Billings, Montana 59101
Principal Investigator: Benjamin T. Marchello
Phone: 800-996-2663
?
mi
from
Billings, MT
Click here to add this to my saved trials
1233 North 30th Street
Billings, Montana 59101
406-237-7000
Principal Investigator: Keren Sturtz
Phone: 406-969-6060
Saint Vincent Healthcare The Sisters of Charity of Leavenworth, Kansas, founded St. Vincent Healthcare in...
?
mi
from
Billings, MT
Click here to add this to my saved trials
Billings, Montana 59102
Principal Investigator: Keren Sturtz
Phone: 800-648-6274
?
mi
from
Billings, MT
Click here to add this to my saved trials
300 N. Seventh St.
Bismarck, North Dakota 58501
(701) 323-6000
Principal Investigator: Preston D. Steen
Phone: 701-323-5760
Sanford Bismarck Medical Center Whether your stay in our hospital is one day for same...
?
mi
from
Bismarck, ND
Click here to add this to my saved trials
1505 Eastland Drive
Bloomington, Illinois 61701
309-662-2102
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare-Bloomington Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood diseases. Our...
?
mi
from
Bloomington, IL
Click here to add this to my saved trials
Boardman, Ohio 44512
Principal Investigator: Howard M. Gross
Phone: 330-629-7500
?
mi
from
Boardman, OH
Click here to add this to my saved trials
100 E Idaho St
Boise, Idaho 83712
(208) 381-2711
Principal Investigator: Gary E. Goodman
Saint Luke's Mountain States Tumor Institute For more than 100 years, St. Luke
?
mi
from
Boise, ID
Click here to add this to my saved trials
Boise, Idaho 83706
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
?
mi
from
Boise, ID
Click here to add this to my saved trials
Bolivar, Missouri 65613
Principal Investigator: Rakesh Gaur
Phone: 800-328-6010
?
mi
from
Bolivar, MO
Click here to add this to my saved trials
Bonne Terre, Missouri 63628
Principal Investigator: Bryan A. Faller
Phone: 314-996-5569
?
mi
from
Bonne Terre, MO
Click here to add this to my saved trials
1100 Balsam Ave
Boulder, Colorado 80304
(303) 440-2273
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Boulder Community Hospital Founded in 1922 as a community-owned and operated not-for-profit hospital, Boulder Community...
?
mi
from
Boulder, CO
Click here to add this to my saved trials
Boulder, Colorado 80303
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
?
mi
from
Boulder, CO
Click here to add this to my saved trials
915 Highland Blvd
Bozeman, Montana 59715
(406) 414-5000
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Bozeman Deaconess Hospital Bozeman Deaconess Hospital is a Joint Commission certified, licensed Level III trauma...
?
mi
from
Bozeman, MT
Click here to add this to my saved trials
Branson, Missouri 65616
Principal Investigator: Jay W. Carlson
Phone: 417-269-4520
?
mi
from
Branson, MO
Click here to add this to my saved trials
Bremerton, Washington 98310
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Bremerton, WA
Click here to add this to my saved trials
Brewer, Maine 04412
Principal Investigator: Thomas H. Openshaw
Phone: 800-987-3005
?
mi
from
Brewer, ME
Click here to add this to my saved trials
7575 Grand River Avenue
Brighton, Michigan 48114
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
?
mi
from
Brighton, MI
Click here to add this to my saved trials
7575 Grand River Avenue
Brighton, Michigan 48114
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
?
mi
from
Brighton, MI
Click here to add this to my saved trials
Bryan, Texas 77802
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Bryan, TX
Click here to add this to my saved trials
Burbank, California
Principal Investigator: Gary E. Goodman
Phone: 818-847-4793
?
mi
from
Burbank, CA
Click here to add this to my saved trials
Burien, Washington 98166
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Burien, WA
Click here to add this to my saved trials
Burlington, Wisconsin 53105
Principal Investigator: Thomas J. Saphner
Phone: 414-302-2304
?
mi
from
Burlington, WI
Click here to add this to my saved trials
201 E Nicollet Blvd
Burnsville, Minnesota 55337
(952) 892-2000
Principal Investigator: David M. King
Phone: 952-993-1517
Fairview Ridges Hospital Fairview Ridges Hospital is a 150-bed, Level III Trauma Care facility, offering...
?
mi
from
Burnsville, MN
Click here to add this to my saved trials
400 South Clark Street
Butte, Montana 59701
406-723-2500
Principal Investigator: Keren Sturtz
Phone: 406-723-2621
Saint James Community Hospital and Cancer Treatment Center St. James Healthcare has played an important...
?
mi
from
Butte, MT
Click here to add this to my saved trials
3123 Medical Dr
Caldwell, Idaho 83605
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
?
mi
from
Caldwell, ID
Click here to add this to my saved trials
210 W Walnut St
Canton, Illinois 61520
309-647-5240
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare - Canton Illinois CancerCare is one of the largest private oncology and hematology...
?
mi
from
Canton, IL
Click here to add this to my saved trials
1600 South Canton Center Road
Canton, Michigan 48188
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
?
mi
from
Canton, MI
Click here to add this to my saved trials
1600 South Canton Center Road
Canton, Michigan 48188
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
?
mi
from
Canton, MI
Click here to add this to my saved trials
Canton, Ohio 44708
Principal Investigator: Mitchell Haut
Phone: 888-293-4673
?
mi
from
Canton, OH
Click here to add this to my saved trials
211 Saint Francis Drive
Cape Girardeau, Missouri 63703
573-331-3000
Principal Investigator: Bryan A. Faller
Phone: 573-334-2230
Saint Francis Medical Center Saint Francis Medical Center is a 282-bed facility serving more than...
?
mi
from
Cape Girardeau, MO
Click here to add this to my saved trials
789 Mt Auburn Rd
Cape Girardeau, Missouri 63703
(573) 519-4725
Principal Investigator: Bryan A. Faller
Phone: 573-651-5550
Southeast Cancer Center SoutheastHEALTH is a far-reaching network of providers and facilities including Southeast Hospital...
?
mi
from
Cape Girardeau, MO
Click here to add this to my saved trials
Carbondale, Illinois 62902
Principal Investigator: Bryan A. Faller
Phone: 618-457-5200
?
mi
from
Carbondale, IL
Click here to add this to my saved trials
401 North Hooper Street
Caro, Michigan 48723
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
?
mi
from
Caro, MI
Click here to add this to my saved trials
Carson City, Nevada 89703
Principal Investigator: John A. Ellerton
Phone: 702-384-0013
?
mi
from
Carson City, NV
Click here to add this to my saved trials
Carterville, Illinois 62918
Principal Investigator: Bryan A. Faller
Phone: 618-985-3333
?
mi
from
Carterville, IL
Click here to add this to my saved trials
160 S Adams St
Carthage, Illinois 62321
(217) 357-6877
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare - Carthage Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood...
?
mi
from
Carthage, IL
Click here to add this to my saved trials
Centerville, Ohio 45459
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
?
mi
from
Centerville, OH
Click here to add this to my saved trials
Centerville, Ohio 45459
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
?
mi
from
Centerville, OH
Click here to add this to my saved trials
Centralia, Illinois 62801
Principal Investigator: Bryan A. Faller
Phone: 217-876-4740
?
mi
from
Centralia, IL
Click here to add this to my saved trials
Centralia, Washington 98531
Principal Investigator: Gary E. Goodman
Phone: 360-412-8958
?
mi
from
Centralia, WA
Click here to add this to my saved trials
Chattanooga, Tennessee 37404
Principal Investigator: Richard L. Deming
?
mi
from
Chattanooga, TN
Click here to add this to my saved trials
775 South Main Street
Chelsea, Michigan 48118
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
?
mi
from
Chelsea, MI
Click here to add this to my saved trials
14650 East Old US Highway 12
Chelsea, Michigan 48118
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
?
mi
from
Chelsea, MI
Click here to add this to my saved trials
Cheyenne, Wyoming 82001
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
?
mi
from
Cheyenne, WY
Click here to add this to my saved trials
303 East Superior Street
Chicago, Illinois 60611
Principal Investigator: Sunandana Chandra
Phone: 312-695-1301
?
mi
from
Chicago, IL
Click here to add this to my saved trials
272 Hospital Rd
Chillicothe, Ohio 45601
740-779-7500
Principal Investigator: Timothy D. Moore
Phone: 877-779-7585
Adena Regional Medical Center Since 1895, Adena Health System has remained focused on its commitment...
?
mi
from
Chillicothe, OH
Click here to add this to my saved trials
12961 27th Ave
Chippewa Falls, Wisconsin 54729
715-738-3700
Principal Investigator: Michael Husak
Phone: 800-782-8581
Marshfield Clinic - Chippewa Center The 15,000 square foot Lake Hallie Center provides urgent care...
?
mi
from
Chippewa Falls, WI
Click here to add this to my saved trials
Cincinnati, Ohio 45242
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Cincinnati, Ohio 45220
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Cincinnati, Ohio 45236
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Cincinnati, Ohio 45255
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Cincinnati, Ohio 45247
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
9280 SE Sunnybrook Blvd #100
Clackamas, Oregon 97015
(503) 513-3300
Principal Investigator: Gary E. Goodman
Phone: 503-215-2614
Clackamas Radiation Oncology Center State-of-the-art technology and compassionate care come together at Clackamas Radiation Oncology...
?
mi
from
Clackamas, OR
Click here to add this to my saved trials
Clackamas, Oregon 97015
Principal Investigator: Gary E. Goodman
Phone: 503-215-2614
?
mi
from
Clackamas, OR
Click here to add this to my saved trials
5680 Bow Pointe Drive
Clarkston, Michigan 48346
Principal Investigator: Tareq Al Baghdadi
Phone: 734-712-3671
?
mi
from
Clarkston, MI
Click here to add this to my saved trials